X4 Pharmaceuticals, Inc.
NCM: XFORLive Quote
📈 ZcoreAI Score
Our AI model analyzes X4 Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get XFOR Z-Score →About X4 Pharmaceuticals, Inc.
Healthcare
Biotechnology
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
X4 Pharmaceuticals, Inc. demonstrates a profit margin of -225.6%, which is below the sector average, suggesting competitive pressure.
The company recently reported 79.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -76.0%, which indicates that capital utilization is currently under pressure.
At a current price of $4.10, XFOR currently sits at the 50th percentile of its 52-week range (Range: $1.35 - $6.84).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$372.77M
Trailing P/E
--
Forward P/E
-4.25
Beta (5Y)
0.33
52W High
$6.84
52W Low
$1.35
Avg Volume
487K
Day High
Day Low